RP24-329J6.5 Inhibitors
RP24-329J6.5 Inhibitors exhibit a wide array of biochemical actions that ultimately converge on the reduction of RP24-329J6.5 activity. For instance, Rapamycin forms a complex with FKBP12 to inhibit mTOR, a kinase that is part of a signaling cascade downstream of RP24-329J6.5, leading to decreased cell proliferation and protein synthesis influenced by RP24-329J6.5.LY294002 and Wortmannin both act as potent inhibitors of PI3K, a key component upstream of Akt signaling, which can affect the function of RP24-329J6.5. By inhibiting this kinase, the indirect result is a reduction of RP24-329J6.5 activity due to a decrease in downstream signaling. Additionally, similar effects arise from the use of U0126, PD98059, and BIX 02189, which are inhibitors targeting MEK and ERK5, components of the MAPK pathway, a crucial signaling mechanism that can govern the expression and activity of RP24-329J6.5. Staurosporine broadly targets protein kinases, potentially impacting various pathways including those in which RP24-329J6.5 is involved, thereby reducing its activity indirectly through widespread kinase inhibition.
In another aspect, SP600125 and SB203580 specifically inhibit JNK and p38 MAPK, respectively, which are implicated in cell stress responses and apoptosis, processes that could be regulated by RP24-329J6.5. Inhibition of these kinases leads to an indirect decrease in RP24-329J6.5's role in these cellular processes. Furthermore, WZ4003 and PF-4708671 inhibit NUAK1 and S6K1, which are associated with cellular stress responses and protein synthesis-processes potentially influenced by RP24-329J6.5. Torin 1, an mTOR inhibitor, also contributes to the attenuation of RP24-329J6.5 activity by influencing cell growth and autophagy, further indicating the complex network of signaling pathways that these inhibitors modulate to achieve the functional inhibition of RP24-329J6.5.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It inhibits protein kinase C which is involved in the phosphorylation of target proteins. Since phosphorylation status can regulate protein activity, staurosporine, by inhibiting kinases, could indirectly lead to the reduced activity of RP24-329J6.5 if it is phosphorylation-dependent. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and affects the mTOR signaling pathway. The mTOR pathway regulates protein synthesis and cell growth. Through the inhibition of mTOR, rapamycin can indirectly decrease the activity of RP24-329J6.5 if RP24-329J6.5 activity is linked to cellular growth signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). PI3K is a critical component of the AKT signaling pathway, which is involved in cell survival and proliferation. By inhibiting PI3K, LY294002 can disrupt downstream signaling and potentially decrease the activity of RP24-329J6.5 if it is regulated by the AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of extracellular signal-regulated kinases (ERK). MEK inhibition by PD98059 impedes the MAPK/ERK pathway, potentially reducing the activity of RP24-329J6.5 if it is modulated by ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in the response to stress and inflammation. Inhibition of p38 by SB203580 could lower the activity of RP24-329J6.5 if it plays a role in stress or inflammation-related signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the regulation of apoptosis and cell proliferation. By inhibiting JNK activity, SP600125 could indirectly affect the activity of RP24-329J6.5 if it is involved in the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, and thus has a similar mechanism of potentially decreasing RP24-329J6.5 activity through the disruption of the AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, affecting the MAPK/ERK pathway akin to PD98059. It can therefore similarly lead to a potential reduction in RP24-329J6.5 activity if this protein is regulated by this pathway. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, which is necessary for pyrimidine synthesis. By inhibiting this enzyme, leflunomide can reduce the proliferation of rapidly dividing cells, potentially affecting RP24-329J6.5 activity if it is associated with cell division. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, specifically targeting BCR-ABL, c-KIT, and PDGF receptors. By inhibiting these kinases, imatinib can interfere with signaling pathways that may regulate the activity of RP24-329J6.5. | ||||||